As the co-chair of the Firm's Private Equity & Venture Capital Group, Jim Barrett is a business and securities lawyer who represents life sciences and other technology companies as well as venture capital and private equity funds. He regularly counsels Boards of Directors and General Partners on corporate governance matters and guides their businesses through all stages of development. Accordingly, Jim concentrates in investment transactions, mergers and acquisitions, securities law and general corporate representation. Jim is listed in the Corporate Law Section of The Best Lawyers in America. Notable Experience · Represented Protient, Inc. in its sale to a major multi-national corporation. · We represented MPM Capital in the acquisition by Novartis AG of a majority stake in Idenix for $255 million, plus contingent payments, as well as in Idenix's IPO and follow-on offering. · The sale of PharmAthene to Healthcare Acquisition Corp., in which we represented Bear Stearns Health Innoventures, HealthCare Ventures and MPM Capital as the major stockholders of PharmAthene. We had previously represented such investors in a $50 million financing of PharmAthene. · The $350 million sale of TriPath Imaging (TPTH), an Ampersand Ventures portfolio company, to Becton, Dickinson and Company (BDX). · The Series A Financing for Syndax Pharmaceuticals Inc., a company that is developing novel oncology products through mechanistically driven combination regimens, in which we represented MPM Capital and Pappas Ventures. · The Series A Financing for Claros Diagnostics, a company that is developing a proprietary microfluidics device to improve diagnostics in prostate cancer and other urology disorders, in which we represented Oxford Bioscience Partners. · The Series A financing for Cequent Pharmaceuticals, a company developing new clinically compatible therapies based on RNA interference, in which we represented Ampersand Ventures. · The Series C Financing for Elixir Pharmaceuticals, a company developing therapeutics to treat age-related diseases, in which we represented MPM Capital. · MPM Capital's investment in Xanodyne Pharmaceuticals, a pain and women's health company, and Xanodyne's simultaneous acquisition of assets from aaiPharma for $209 million. · The acquisition of Trek Diagnostic Systems and simultaneous Series A Financing of Magellan Biosciences, a clinical diagnostics company whose lead investors are Ampersand Ventures and Abingworth Management. · The sale by MPM Capital of its interest in Idea AG to Celtic Pharmaceutical Holdings L.P. · Oxford Bioscience Partners' $20 million investment in and reorganization of Alantos Pharmaceuticals AG as a Delaware corporation. · Represented Cerimon Pharmaceuticals in $70 million Series A Preferred Stock financing. · Ampersand's and SV Life Sciences' investment in M2 Worldwide Corporation (Medifacts), a Maryland-based provider of cardiac monitoring and other clinical trial services. · Represented Open Ratings, Inc., a venture-backed on-line supply chain management company, in its acquisition by Dun & Bradstreet, Inc. · Ampersand's buyout of Princeton Radiology Pharmaceutical Research, a Princeton, New Jersey based provider of radiological services for use in clinical and other environments. · Represented a syndicate of investors, including MPM Capital and Oxford Bioscience Partners, in its investment in Radius Health, Inc. · Represented Transport Pharmaceuticals in its conversion to a corporation and $27 million initial round of financing. · Represented Magellan Biosciences, a clinical diagnostics company, in its acquisition of TekCel, Inc. · General counsel to Ampersand Ventures. · General counsel to Cequent Pharmaceuticals, Inc. · General counsel to EnVivo Pharmaceuticals, Inc. · General counsel to Kamylon Capital. · General counsel to Magellan Biosciences, Inc. · General counsel to MPM Capital. · General counsel to RAND Worldwide, Inc. · General counsel to Stemline Therapeutics, Inc. Recent Speaking Engagements and Publications · "Law Firms Getting Their Own IPO Lift," featured and quoted, Boston Business Journal, June 10, 2011. · "How Venture Capital Fund Managers May Avoid Investment Adviser Regulation . . . But Not Reporting - Fund Managers Should Submit Comments to the SEC," co-author, Edwards Angell Palmer & Dodge Client Advisory, November 2010. · "Venture Capital: Through the Storm," moderator, Fifth Annual Private Equity and Growth Ventures Conference, February 5, 2010. · "Hedge funds give private equity a run for its money," quoted, Boston Business Journal, October 16, 2006. · "Intellectual Property and Licensing Pitfalls," author, Venture Capital Journal, December 31, 2004. · "Intellectual property is a terrible thing to waste," author, Mass High Tech, December 31, 2004. · "Managing Risk Through the Use of Milestone-based Conversion Rate Adjustments," co-author, Venture Capital Journal, July 21, 2004. · "Massachusetts Superior Court Holds Term Sheet Provisions for Detachable Warrants Ambiguous - Venture Investors' Warrants Invalidated," co-author, January 27, 2003. · "CalPERS Files Its Opposition to Disclosure," author, November 5, 2002. · "The USA PATRIOT Act: Compliance Issues for Mutual Funds and Private Investment Funds," co-author, March 25, 2002. · "Portfolio companies face unique bankruptcy concerns," co-author, Mass High Tech, June 25 - July 1, 2001. News & Publications June 2011, Client Advisory - SEC Issues Final Rules on Exemptions for Managers of Venture Capital Funds and Other Funds with Less Than $150 Million in Assets
Registration for Non-Exempt Advisers Postponed Until March 30, 2012 June 14, 2011, Legal 500's 2011 US Guide Recognizes EAPD in Three Categories November 2010, Client Advisory - How Venture Capital Fund Managers May Avoid Investment Adviser Regulation . . . But Not Reporting
Fund Managers Should Submit Comments to the SEC October 7, 2010, EAPD Attorneys Selected For Inclusion in Super Lawyers 2010 August 10, 2010, Sixty EAPD Attorneys Recognized by the Best Lawyers in America June 16, 2010, EAPD Recognized in 2010 US Edition of Legal 500 November 6, 2009, EAPD Attorneys Selected For Inclusion in Super Lawyers 2009 September 1, 2009, 62 EAPD Attorneys Recognized as Best Lawyers in America 2010 July 31, 2009, EAPD Represents MPM Capital LLC and Healthcare Ventures LLC June 2009, Edwards Angell Palmer & Dodge Mergers & Acquisitions and Venture Capital Practices recognized for excellence by The Legal 500 US, 2009 Edition November 1, 2006, Edwards Angell Palmer & Dodge Attorneys Honored as Massachusetts Super Lawyers December 31, 2004, Intellectual Property and Licensing Pitfalls December 31, 2004, Intellectual property is a terrible thing to waste July 21, 2004, Managing Risk Through the Use of Milestone-based Conversion Rate Adjustments January 27, 2003, Massachusetts Superior Court Holds Term Sheet Provisions for Detachable Warrants Ambiguous - Venture Investors' Warrants Invalidated November 5, 2002, San Jose Mercury News vs. CalPERS: CalPERS Files Its Opposition to Disclosure May 30, 2002, Venture Capital Firms: Getting the Right Rights March 25, 2002, The USA PATRIOT Act: Compliance Issues for Mutual Funds and Private Investment Funds September 12, 2001, Portfolio Companies Face Unique Bankruptcy Concerns May 22, 2000, Structural Issues for Founders of Internet/E-Commerce Businesses Events February 3, 2012, Hanover, NH, 2012 Tuck Private Equity and Growth Ventures Conference January 19, 2012, Boston, MA, General Counsel Roundtable Series November 10, 2011, Boston, MA, General Counsel Roundtable Series February 5, 2010, Hanover, NH, Fifth Annual Private Equity and Growth Ventures Conference Industries · Life Sciences |